CJC-1295 & Ipamorelin Blend

Premium CJC‑1295 & Ipamorelin Blend Research Peptide — Dual‑Pathway GHRH/GHSR Formulation for Laboratory Use

Product Overview

Premium CJC‑1295 & Ipamorelin Blend is a research‑grade synergistic peptide combination pairing a growth hormone‑releasing hormone (GHRH) analog with a highly selective ghrelin receptor agonist. It is supplied as a sterile lyophilized powder in sealed vials. Each package contains ten vials, with each vial containing 5 mg of CJC‑1295 and 5 mg of Ipamorelin (total 10 mg). This product is manufactured exclusively for scientific investigation and in vitro laboratory experimentation.

Key Specifications at a Glance:

• Quantity: 10 vials per pack

• Composition: CJC‑1295 (5 mg), Ipamorelin (5 mg)

• Total per vial: 10 mg

• Form: Lyophilized (freeze‑dried) powder

• Purity: ≥99% verified by third‑party testing

• Research Focus: Growth hormone axis dual‑pathway modulation (GHRHR and GHSR)

• Research Use Only: Not for human or animal consumption

Understanding the Blend: Dual‑Pathway GHRH/GHSR Research Context

The CJC‑1295 & Ipamorelin Blend combines two distinct classes of growth hormone secretagogues that work through complementary mechanisms. This dual‑pathway approach allows researchers to study the growth hormone axis from multiple angles simultaneously.

The Two Components of the Blend:

The Complementary Pathways:
Growth hormone secretion from the pituitary is regulated by two primary hypothalamic signals:

• Growth Hormone‑Releasing Hormone (GHRH): Binds to GHRH receptors (GHRHR) on pituitary somatotrophs, stimulating GH synthesis and pulsatile release.

• Ghrelin (acting on GHSR): Binds to growth hormone secretagogue receptors (GHSR‑1a), amplifying the amplitude of GH pulses.

CJC‑1295 mimics GHRH, extending the duration of GH pulses, while Ipamorelin mimics ghrelin’s GH‑releasing effect without stimulating appetite or elevating cortisol. By activating both pathways, the blend offers an integrated research model for studying the neuroendocrine control of GH secretion.

Third‑Party Testing and Quality Assurance

Every batch of the Premium CJC‑1295 & Ipamorelin Blend undergoes rigorous independent analytical testing to verify identity, purity, and consistency. This third‑party testing ensures that researchers receive a product that meets strict quality specifications before it is approved for release.

The testing process includes:

• Identity verification through mass spectrometry for both peptides

• Purity analysis using high‑performance liquid chromatography (HPLC) — ≥99% per component

• Batch‑to‑batch consistency checks

• Endotoxin testing (<0.05 EU/mg) for cell culture applications

• Residual solvent analysis to confirm complete lyophilization

With a verified purity of ≥99% for each peptide, this blend meets the high standards required for serious laboratory research applications. Each vial contains only the lyophilized research compound combination with no unnecessary additives, fillers, or excipients. Batch‑specific Certificates of Analysis (CoA) are available upon request.

Component Profiles: The Two Peptides

CJC‑1295 (5 mg) — The GHRH Analog for Sustained GHRHR Activation

CJC‑1295 (No DAC) is a synthetic 30‑amino acid analog of growth hormone‑releasing hormone (GHRH). It is specifically modified to resist enzymatic degradation, providing more sustained activation of GHRH receptors compared to native GHRH. CJC-1295 & Ipamorelin Blend

Key Research Interests:

• GHRH receptor (GHRHR) activation and signaling

• Growth hormone synthesis and secretion studies

• Pituitary somatotroph function

• Prolonged receptor activation kinetics

Molecular Characteristics:

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

• Molecular Mass: ≈3367 g/mol

• Sequence: Modified GHRH analog with enhanced stability

Structural Features:

• 30‑amino acid synthetic peptide

• Resists dipeptidyl peptidase‑IV (DPP‑IV) degradation

• Specifically targets GHRH receptors on pituitary somatotrophs

Ipamorelin (5 mg) — The Selective GHSR Agonist

Ipamorelin is a synthetic pentapeptide and a highly selective agonist of the ghrelin receptor (GHSR‑1a). As a third‑generation growth hormone secretagogue, it stimulates GH release without affecting ACTH, cortisol, or prolactin levels. CJC-1295 & Ipamorelin Blend

Key Research Interests:

• GHSR activation and Gαq signaling

• Growth hormone pulse amplitude modulation

• Isolated GH axis activation (minimal off‑target effects)

Molecular Characteristics:

• Molecular Formula: C₃₈H₄₉N₉O₅

• Molecular Mass: 711.9 g/mol

• CAS Number: 170851‑70‑4

• Sequence: Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂

Structural Features:

• Pentapeptide (5 amino acids)

• Contains non‑standard amino acids (Aib, D‑2‑Nal, D‑Phe) for enhanced stability

• Selective for GHSR with minimal effects on other pituitary hormones

The Synergy: Why Combine CJC‑1295 and Ipamorelin?

Single‑pathway growth hormone stimulation often produces limited responses due to the complex, redundant regulation of the GH axis. The CJC‑1295 & Ipamorelin Blend was designed to address both major regulatory pathways simultaneously. CJC-1295 & Ipamorelin Blend

The Dual‑Pathway Principle:

Why Dual‑Pathway Research Matters:

• GHRH receptor activation increases GH synthesis and primes somatotrophs

• GHSR activation (via ghrelin receptor) potentiates the amount of GH released per pulse

• Combined activation produces a more robust and physiological GH secretory pattern

• Studying both pathways simultaneously provides a more complete picture of GH axis regulation

Comparing Single vs. Combined Pathway Activation:

Chemical and Physical Properties

Molecular Characteristics of Each Component

Physical Form and Storage

The product is supplied as a lyophilized (freeze‑dried) powder within a sterile, sealed vial. The blend appears as a white to off‑white homogeneous powder. CJC-1295 & Ipamorelin Blend

Recommended Storage Conditions:

• Store lyophilized powder at -20°C (-4°F) or below for long‑term preservation (≥24 months)

• Protect from light exposure

• Keep desiccated to prevent moisture absorption

• Allow vial to reach room temperature before opening to avoid condensation

• Avoid repeated freeze‑thaw cycles once reconstituted

Reconstituted Solution Storage:
Once reconstituted, the solution should be stored at 2‑8°C (refrigerated) and used within 30 days. For extended storage after reconstitution, freeze aliquots at -20°C or -80°C, preferably with a carrier protein (e.g., 0.1% BSA) to enhance stability. CJC-1295 & Ipamorelin Blend

Solubility Information:
The blend is soluble in sterile water or bacteriostatic water at concentrations ≥1 mg/mL per component. CJC-1295 & Ipamorelin Blend

Intended Use and Regulatory Status

Research Use Only

The CJC‑1295 & Ipamorelin Blend is classified as a research chemical and is intended exclusively for laboratory and in vitro experimentation. This designation means the product is sold strictly for:

• In vitro testing — experiments conducted in controlled laboratory environments

• Cell culture studies — investigating GHRHR and GHSR signaling in pituitary cell lines

• Receptor binding assays — studying dual‑pathway activation of GH secretion

• Growth hormone axis research — exploring frequency vs. amplitude modulation of GH pulses

• GPCR signaling studies — comparing Gs (GHRHR) and Gαq (GHSR) pathways

• Analytical research — chemical analysis and characterization

• Scientific investigation — basic research into GHRH and ghrelin receptor pharmacology

Important Regulatory Notice

This product is not a drug, food, cosmetic, or medical device. Bodily introduction of any kind into humans or animals is strictly forbidden by law. The product should only be handled by licensed, qualified professionals working in appropriate laboratory facilities.

The supplier is a chemical supplier, not a compounding pharmacy or outsourcing facility under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. All product information provided is for educational and research purposes only and does not constitute medical advice or clinical recommendations. CJC-1295 & Ipamorelin Blend

Handling and Safety Guidelines

Professional Handling Required

The CJC‑1295 & Ipamorelin Blend should only be handled by trained laboratory personnel wearing appropriate personal protective equipment (PPE), including:

• Laboratory coat

• Nitrile gloves

• Safety goggles or face shield

• Appropriate respiratory protection if aerosolization is possible

Reconstitution Protocol

For laboratory use, the lyophilized powder should be reconstituted with a sterile, compatible solvent. Standard practice includes:

1. Allow the sealed vial to reach room temperature — approximately 15‑30 minutes

2. Clean the rubber stopper with an alcohol swab

3. Add the calculated volume of solvent to achieve desired concentration

4. Gently swirl or roll the vial between palms — do not shake vigorously to avoid foaming

5. Allow complete dissolution before use — this typically takes 5‑10 minutes

Reconstitution Example for the Blend (5 mg/5 mg = 10 mg total):

• For a total concentration of 5 mg/mL (2.5 mg/mL each): add 2 mL of sterile solvent

• For 10 mg/mL (5 mg/mL each): add 1 mL of solvent

• For 2 mg/mL (1 mg/mL each): add 5 mL of solvent

Always verify calculations based on specific experimental requirements.

Solvent Considerations:
Both peptides are water‑soluble. Sterile water for injection or bacteriostatic water is recommended. For long‑term stability, aliquots can be frozen after reconstitution in bacteriostatic water (which contains 0.9% benzyl alcohol as a preservative). CJC-1295 & Ipamorelin Blend

Disposal Considerations

Dispose of the blend and any contaminated materials in accordance with federal, state, and local regulations for chemical waste disposal. Do not dispose of in regular trash or down drains unless permitted by local guidelines. CJC-1295 & Ipamorelin Blend

Research Applications

The CJC‑1295 & Ipamorelin Blend is used in various laboratory research contexts, primarily focused on GH axis regulation, GPCR signaling, and pituitary biology. Typical applications include:

GHRHR and GHSR Dual‑Pathway Studies:
The primary research interest in this blend revolves around the simultaneous activation of both major GH regulatory pathways. Researchers use the blend to study:

• GHRHR and GHSR signaling interactions and crosstalk

• Synergistic effects on GH secretion amplitude and pulse extension

• Comparative signaling profiles of single vs. dual pathway activation

• Receptor desensitization and intracellular trafficking

GPCR Signaling Research:

• CJC‑1295 activates GHRHR (Gs‑coupled → cAMP/PKA pathway)

• Ipamorelin activates GHSR (Gαq‑coupled → PLC/IP₃/calcium pathway)

• The blend allows direct comparison of Gs vs. Gαq signaling in the same cell type

Pituitary Cell Culture Studies:
Researchers use the blend in primary pituitary cell cultures or immortalized somatotroph cell lines to investigate:

• GH synthesis and secretion dynamics under combined GHRH + GHSR stimulation

• Somatotroph responsiveness and receptor regulation

• Downstream transcription factor activation (CREB, Elk‑1)

In Vitro GH Pulse Modelling:
The complementary mechanisms of CJC‑1295 (extending pulse duration) and Ipamorelin (amplifying pulse amplitude) allow researchers to model physiologically relevant GH pulsatility in vitro.

Comparative Pharmacological Studies:
The blend enables direct comparison of:

• GHRH analogs vs. GHSR agonists

• Additive vs. synergistic effects on GH release

• Species‑specific differences in receptor pharmacology

Cell Signaling and Transcriptional Analysis:
Researchers can assess activation of signaling kinases (ERK, AKT), calcium flux, and immediate early gene expression (c‑Fos, JunB) following dual pathway activation.

Researchers should design their experimental protocols based on peer‑reviewed literature and established laboratory practices specific to growth hormone secretagogues.

What Makes This Product Different

Pre‑Formulated Dual‑Pathway Blend

Unlike individual research peptides that require separate handling, reconstitution, and combination, this blend combines two complementary growth hormone secretagogues into a single vial at an optimal 1:1 ratio. This structured approach supports consistency, efficiency, and reproducibility in research settings. CJC-1295 & Ipamorelin Blend

Complementary Mechanisms

The blend combines a GHRH analog (CJC‑1295) with a GHSR agonist (Ipamorelin), targeting both major pathways that regulate GH secretion. This dual‑pathway approach allows researchers to study frequency modulation (GHRH‑dominant) and amplitude modulation (GHSR‑dominant) simultaneously.

Selective GHSR Activation

Ipamorelin demonstrates high selectivity for GH release with minimal effects on other pituitary hormones such as cortisol and prolactin, making it a refined research tool for studying isolated GH axis effects. CJC-1295 & Ipamorelin Blend

Optimized 1:1 Ratio

The 5 mg/5 mg (1:1) ratio reflects the different effective concentration ranges of each peptide, providing a balanced formulation for dual‑pathway studies without the need for separate titration.

Rigorous Quality Control

Unlike research chemicals sold without verification, this blend comes with documented third‑party testing for every batch, including HPLC purity analysis, mass spectrometry identity confirmation, and endotoxin testing (<0.05 EU/mg). CJC-1295 & Ipamorelin Blend

Batch Traceability

Each package of the blend includes batch identification numbers that allow researchers to trace their material back to original manufacturing and testing records. This traceability is essential for reproducible research and quality documentation. CJC-1295 & Ipamorelin Blend

Frequently Asked Questions for Researchers

What is the composition of the blend?

Each vial contains 5 mg of CJC‑1295 (No DAC) and 5 mg of Ipamorelin, for a total of 10 mg per vial. Packages contain 10 vials (total 50 mg of each peptide, 100 mg total blend).

What is the purity level?

Each batch is tested to verify purity of ≥99% for both components via HPLC, with identity confirmed by mass spectrometry. Individual certificates of analysis are available upon request.

What is the difference between CJC‑1295 with DAC and without DAC?

CJC‑1295 with DAC (Drug Affinity Complex) binds to albumin, giving it a half‑life of several days. CJC‑1295 without DAC (sometimes called Modified GRF 1‑29) has a shorter half‑life (minutes), which is preferred for studying more physiological pulsatile GH release. The version in this blend is CJC‑1295 (No DAC). CJC-1295 & Ipamorelin Blend

How should the lyophilized powder be stored?

Store at -20°C or below, protected from light and moisture. The lyophilized powder is stable for at least 24 months under these conditions. Avoid repeated freeze‑thaw cycles once reconstituted.

What solvent should be used for reconstitution?

Both peptides are water‑soluble. Bacteriostatic water is recommended to maintain sterility during repeated use. For single‑use applications, sterile water for injection is also suitable.

Is this product sterile?

The lyophilized powder is manufactured under aseptic conditions. Researchers should follow standard laboratory practices for handling research chemicals. For cell culture applications, additional filtration using a 0.22‑micron filter may be appropriate.

What is the ratio of CJC‑1295 to Ipamorelin?

The blend contains a 1:1 ratio — 5 mg of each peptide per vial.

How does this blend differ from using the peptides separately?

The pre‑formulated blend ensures consistent 1:1 ratios across experiments and simplifies handling. For research requiring independent dose variation of each peptide, separate vials may be preferred.

What receptors do these peptides target?

CJC‑1295 targets the GHRH receptor (GHRHR, a Gs‑coupled GPCR). Ipamorelin targets the ghrelin receptor GHSR‑1a (a Gαq‑coupled GPCR).

Can this blend be used in combination with other research reagents?

Researchers should determine compatibility based on their specific experimental design. Standard practice includes testing interactions in control experiments before full‑scale implementation.

Final Notes for Laboratory Researchers

The Premium CJC‑1295 & Ipamorelin Blend represents a high‑purity research tool for qualified professionals conducting legitimate scientific investigations into growth hormone axis regulation, GHRHR and GHSR signaling, pituitary somatotroph function, and related endocrinological fields. With documented third‑party testing, complete chemical specifications, and appropriate packaging for laboratory use, this product meets the standards expected by serious researchers.

The pre‑formulated 1:1 blend offers researchers the ability to study dual‑pathway growth hormone regulation simultaneously — GHRH receptor activation (pulse frequency/extension) and GHSR activation (pulse amplitude) — providing a more complete picture of GH neuroendocrine control than either pathway alone. CJC-1295 & Ipamorelin Blend

For research use only. Not for human or animal consumption. Handle only in appropriate laboratory facilities with proper safety equipment and training. CJC-1295 & Ipamorelin Blend